RBC Life Sciences, Inc. (RBCL)

[Helter Skelter]

RBC Life Sciences Reports 16% Second Quarter Sales Growth

Press Release Source: RBC Life Sciences, Inc. On Tuesday August 3, 2010, 8:00 am EDT

IRVING, Texas, Aug. 3 /PRNewswire-FirstCall/ -- (RBC Life Sciences: OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported company-wide net sales of $7.8 million for the second quarter ended June 30, 2010, compared to net sales of $6.8 million for the same period during 2009, an increase of 16%. Net sales for the six months ended June 30, 2010 also increased 16% to $14.8 million compared to net sales of $12.8 million during the same period in 2009.

For the second quarter of 2010, the Company reported net earnings of $172,000, or $0.01 per share, compared to net earnings of $277,000, or $0.01 per share, during the same quarter in 2009. Net earnings for the six months ended June 30, 2010 were $383,000, or $0.02 per share, compared to $106,000, or $0.00 per share, during the same period in 2009.

"We are pleased to report year over year sales growth in both of our industry segments as well as significant improvement in earnings during the first six months of 2010," said RBC Life Sciences President and CEO, Clinton H. Howard. "We are particularly pleased with continued recovery of our international licensee business after the challenges we faced in that market last year."

Net sales to licensees, which represent 59% of consolidated net sales, increased 28% during the first six months of 2010 over the comparable period in 2009.

About RBC Life Sciences
Through wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

http://finance.yahoo.com/news/RBC-Life-Sciences-Reports-16-prnews-2468334811.html?x=0&.v=1